Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes.
angiogenesis
biomarkers
circulating cells
everolimus
pancreatic neuroendocrine tumor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Sep 2022
15 Sep 2022
Historique:
received:
28
07
2022
revised:
30
08
2022
accepted:
05
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
The success of targeted therapies in the treatment of pancreatic neuroendocrine tumors has emphasized the strategy of targeting angiogenesis and the PI3K/AKT/mTOR pathway. However, the major challenge in the targeted era remains the early identification of resistant tumors especially when the efficacy is rarely associated to a clear tumor shrinkage at by imaging assessment. In this prospective study (NCT02305810) we investigated the predictive and prognostic role of soluble biomarkers of angiogenesis turnover (VEGF, bFGF, VEGFR2, TSP-1) circulating endothelial cells and progenitors, in 43 patients with metastatic panNET receiving everolimus. Among all tested biomarkers, we found a specific subpopulation of circulating cells, CD31+CD140b-, with a significantly increased tumor progression hazard for values less or equal to the first quartile. Our study suggested the evidence that circulating cells might be surrogate biomarkers of angiogenesis activity in patients treated with everolimus and their baseline levels can be correlated with survival. However, further studies are now needed to validate the role of these cells as surrogate markers for the selection of patients to be candidates for antiangiogenic treatments.
Sections du résumé
BACKGROUND
BACKGROUND
The success of targeted therapies in the treatment of pancreatic neuroendocrine tumors has emphasized the strategy of targeting angiogenesis and the PI3K/AKT/mTOR pathway. However, the major challenge in the targeted era remains the early identification of resistant tumors especially when the efficacy is rarely associated to a clear tumor shrinkage at by imaging assessment.
METHODS
METHODS
In this prospective study (NCT02305810) we investigated the predictive and prognostic role of soluble biomarkers of angiogenesis turnover (VEGF, bFGF, VEGFR2, TSP-1) circulating endothelial cells and progenitors, in 43 patients with metastatic panNET receiving everolimus.
RESULTS
RESULTS
Among all tested biomarkers, we found a specific subpopulation of circulating cells, CD31+CD140b-, with a significantly increased tumor progression hazard for values less or equal to the first quartile.
CONCLUSION
CONCLUSIONS
Our study suggested the evidence that circulating cells might be surrogate biomarkers of angiogenesis activity in patients treated with everolimus and their baseline levels can be correlated with survival. However, further studies are now needed to validate the role of these cells as surrogate markers for the selection of patients to be candidates for antiangiogenic treatments.
Identifiants
pubmed: 36139632
pii: cancers14184471
doi: 10.3390/cancers14184471
pmc: PMC9497075
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
N Engl J Med. 2011 Feb 10;364(6):514-23
pubmed: 21306238
PLoS One. 2014 Dec 05;9(12):e112456
pubmed: 25479359
J Clin Oncol. 2016 Nov 10;34(32):3906-3913
pubmed: 27621394
Neuroendocrinology. 2013;97(1):45-56
pubmed: 22538258
Clin Cancer Res. 2009 Mar 1;15(5):1612-22
pubmed: 19223496
Cancer. 2007 Apr 15;109(8):1478-86
pubmed: 17340592
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Clin Oncol. 2008 Oct 20;26(30):4899-905
pubmed: 18794539
J Transl Med. 2007 Jul 02;5:32
pubmed: 17605814
Future Oncol. 2019 Jun;15(17):1997-2007
pubmed: 31084373
Cancer. 2013 Jan 15;119(2):313-24
pubmed: 22811049
Tissue Cell. 1986;18(2):153-74
pubmed: 3085281
J Clin Oncol. 2013 Sep 20;31(27):3418-25
pubmed: 23980085
J Clin Oncol. 2010 Jan 10;28(2):245-55
pubmed: 19917848
Blood. 2006 Jul 15;108(2):452-9
pubmed: 16543470
Clin Cancer Res. 2009 Dec 15;15(24):7652-7657
pubmed: 19996223
Cancer Cell. 2012 Jan 17;21(1):66-81
pubmed: 22264789
Nat Rev Cancer. 2006 Nov;6(11):835-45
pubmed: 17036040
Br J Cancer. 2015 Mar 31;112(7):1199-205
pubmed: 25756398
Int J Cancer. 2011 Sep 15;129(6):1344-50
pubmed: 21128230
Ann Oncol. 2008 Oct;19(10):1727-33
pubmed: 18515795
Target Oncol. 2017 Oct;12(5):611-622
pubmed: 28634872
Anticancer Res. 2008 Nov-Dec;28(6A):3801-8
pubmed: 19189667
Br J Cancer. 2014 Jan 7;110(1):115-22
pubmed: 24231952
Cancer Res. 2006 Feb 1;66(3):1500-8
pubmed: 16452206
Clin Cancer Res. 2007 Jan 1;13(1):187-96
pubmed: 17200354
Clin Cancer Res. 2009 Jan 1;15(1):267-73
pubmed: 19118054
In Vivo. 2013 Jan-Feb;27(1):61-6
pubmed: 23239853
J Clin Oncol. 2006 Jan 1;24(1):25-35
pubmed: 16314617